{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:59:47Z","timestamp":1792605587862,"version":"4.5.0"},"reference-count":93,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AIL Ravenna (Associazione Italiana Leucemie)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has established itself as a core treatment for newly diagnosed multiple myeloma (NDMM) patients in the past 30 years. Induction therapy, HDM-ASCT, and subsequent consolidation and maintenance therapy comprise the current fundamental framework for MM treatment. The introduction of anti-CD38 monoclonal antibodies such as daratumumab and isatuximab has changed the treatment paradigm for transplant-eligible NDMM patients in that quadruplets have become the new standard induction therapy. The treatment landscape of MM is undergoing a transformative shift with the introduction of potent new immunotherapies, such as chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), which are currently used in the relapsed\/refractory setting (RRMM) and are already being tested in the NDMM. This review will focus on the incorporation of immunotherapy in the treatment scenario of NDMM patients eligible for ASCT.<\/jats:p>","DOI":"10.3390\/cells13100853","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:26:17Z","timestamp":1715858777000},"page":"853","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy"],"prefix":"10.3390","volume":"13","author":[{"given":"Serena","family":"Rocchi","sequence":"first","affiliation":[{"name":"Hematology Unit and Romagna Metropolitan Transplant Network\u2014Ravenna, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice Anna","family":"Zannetti","sequence":"additional","affiliation":[{"name":"Hematology Unit and Romagna Metropolitan Transplant Network\u2014Ravenna, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0515","authenticated-orcid":false,"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[{"name":"Hematology Unit and Romagna Metropolitan Transplant Network\u2014Ravenna, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-7167","authenticated-orcid":false,"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[{"name":"Hematology Unit and Romagna Metropolitan Transplant Network\u2014Ravenna, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","article-title":"Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An update","volume":"12","author":"Bazarbachi","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood.2020008735","article-title":"How I treat frontline transplantation-eligible multiple myeloma","volume":"139","author":"Perrot","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"EHA Guidelines Committee. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_5","first-page":"e528","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/OP.21.00032","article-title":"Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift","volume":"17","author":"Mohan","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific Antibodies in Multiple Myeloma: Present and Future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"for the European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: A position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.clml.2023.07.001","article-title":"Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma","volume":"23","author":"Lonial","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.hoc.2023.12.007","article-title":"Management of Newly Diagnosed Multiple Myeloma Today, and in the Future","volume":"38","author":"Devasia","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): An open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): Final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102785","DOI":"10.1016\/j.transci.2020.102785","article-title":"New Horizons on stem cell cryopreservation through the artificial eyes of CD 34+, using modern flow cytometry tools","volume":"59","author":"Lanza","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103830","DOI":"10.1016\/j.transci.2023.103830","article-title":"Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection","volume":"62","author":"Lanza","year":"2023","journal-title":"Transfus. Apher. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","article-title":"Low Dose Cyclophosphamide versus Intermediate-High Dose Cyclophosphamide versus G-CSF alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.14008","article-title":"Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody","volume":"111","author":"Seth","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-018-0119-4","article-title":"Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth","volume":"7","author":"Ma","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_41","unstructured":"Zappaterra, A., Civettini, I., Cafro, A.M., Pezzetti, L., Pierini, S., Anghilieri, M., Bellio, L., Bertazzoni, P., Grillo, G., and Minga, P. (Blood Transfus, 2024). Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients, Blood Transfus, ahead of print."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000530056","article-title":"Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients","volume":"50","author":"Sauer","year":"2023","journal-title":"Transfus. Med. Hemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"64","author":"Papaiakovou","year":"2023","journal-title":"Leuk. Lymphoma."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"340.e1","DOI":"10.1016\/j.jtct.2023.02.013","article-title":"Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience","volume":"29","author":"Thurlapati","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kauer, J., Freundt, E.P., Schmitt, A., Weinhold, N., Mai, E.K., M\u00fcller-Tidow, C., Goldschmidt, H., Raab, M.S., Kriegsmann, K., and Sauer, S. (2023). Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: A single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11507-9"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kleber, M., Ntanasis-Stathopoulos, I., and Terpos, E. (2021). BCMA in Multiple Myeloma\u2014A Promising Key to Therapy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184088"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Aleman","year":"2021","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mishra, A.K., Gupta, A., Dagar, G., Das, D., Chakraborty, A., Haque, S., Prasad, C.P., Singh, A., Bhat, A.A., and Macha, M.A. (2023). CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. Vaccines, 11.","DOI":"10.3390\/vaccines11111721"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtageneautoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1182\/blood-2022-159156","article-title":"T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma","volume":"140","author":"Mikkilineni","year":"2022","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1182\/blood-2022-168610","article-title":"Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed\/Refractory (r\/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Du","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Hosny, M., Verkleij, C.P.M., van der Schans, J., Frerichs, K.A., Mutis, T., Zweegman, S., and van de Donk, N.W.C.J. (2021). Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194593"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/fon-2023-0171","article-title":"Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma","volume":"19","author":"Moreau","year":"2023","journal-title":"Future Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.HS9.0000843628.63947.e4","article-title":"Evaluating Teclistamab in patients with relapsed\/refractory Multiple Myeloma following exposure to other B-Cell Maturation Antigen (BCMA)-Targeted agents","volume":"6","author":"Touzeau","year":"2022","journal-title":"HemaSphere"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"TPS8065","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","article-title":"MagnetisMM-6: A phase 3 study of Elranatanab + Daratumumab + Lenalidomide vs Daratumumab + Lenalidomide + Dexamethasone in transplant ineligible patients with Newly Diagnosed Multiple Myeloma","volume":"41","author":"Grosicki","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed\/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2023-179356","article-title":"Trial in Progress: A Phase 2 Study of Linvoseltamab for the Treatment of High-Risk Smoldering Multiple Myeloma (LINKER-SMM1)","volume":"142","author":"Mateos","year":"2023","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","article-title":"Alnuctamab (ALNUC.; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) \u00d7 CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2023-182345","article-title":"Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC\u00ae) Targeting B Cell Maturation Antigen (BCMA) for Relapsed\/Refractory Multiple Myeloma (MM)","volume":"142","author":"Madan","year":"2023","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: A narrative review","volume":"14","author":"Pillarisetti","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated Results of Talquetamab, a GPRC5D\u00d7CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1\/2 MonumenTAL-1 Study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.HS9.0000843612.41180.42","article-title":"S180: RG6234, a novel GPRC5D T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed \/refractory multiple myeloma: Preliminary results from a first-in-human trial","volume":"6","author":"Hutchings","year":"2022","journal-title":"HemaSphere"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study","volume":"140","author":"Mazza","year":"2022","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1182\/blood-2023-177669","article-title":"MD8* Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed\/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody","volume":"142","author":"Dekhtiarenko","year":"2023","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"TPS8066","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066","article-title":"MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of Elranatanab versus Lenalidomide in post-transplant patients with Newly Diagnosed Multiple Myeloma","volume":"41","author":"Mateos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Mo, C.C., Hartley-Brown, M.A., Midha, S., and Richardson, P.G. (2023). Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease\/Risk-Adapted Therapy. Cancers, 15.","DOI":"10.3390\/cancers15245709"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/10\/853\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:43:41Z","timestamp":1760107421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/10\/853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":93,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cells13100853"],"URL":"https:\/\/doi.org\/10.3390\/cells13100853","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}